🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out our review about Biomolecular condensates and cancer. Fun to write this together with Richard Young and Isaac Klein. authors.elsevier.com/c/1cNFW5TA51TI…

Condensates are membrane-less organelles that compartmentalize proteins and RNA. Here, Ann Boija, Isaac Klein & Richard Young summarize how studying condensates advances our understanding of cancer and could lead to novel therapeutics. Via Cancer Cell: bit.ly/35C5dGU

We are thrilled to announce that two papers from Whitehead Institute researchers are in the running for STAT' annual biomedical research tournament, #STATmadness! Cast your vote in the first round today! MIT Biology MIT Science statnews.com/feature/stat-m…

Whitehead Institute is neck and neck in this round of #STATmadness! Help us out by voting for our paper from the Young Lab Richard Young on where cancer drugs go in the body. ow.ly/ynu750DVvvQ

All good things come from coffee!!

Congratulations to a great team on this Mass General / Dana-Farber / Brigham family collaboration! "Impact of cancer history on outcomes among hospitalized COVID-19 patients". pubmed.ncbi.nlm.nih.gov/33856099/

Thrilled to join Dewpoint Therapeutics as Chief Scientific Officer. Thanks for welcoming me to the team. Onward! dewpointx.com

We're delighted to welcome Isaac Klein to our team as Chief Scientific Officer. His expertise and intense interest in the meeting point between #BiomolecularCondensates and disease will prove invaluable as we advance programs toward the clinic. dewpointx.com/news/dewpoint-…

We’re pleased to announce the close of our series C financing. As the leader in #condensate drug discovery and development, we’re excited to further our platforms and add new capabilities to help advance potential therapeutics for patients affected by a wide range of diseases.

Congratulations to the whole Dewpoint Therapeutics team on reaching this important milestone. ​ We're proud to support you in your mission to translate condensate biology into treatments for the world’s toughest diseases.

SoftBank led a $150 million Series C for Dewpoint, the company announced Thursday. Those funds will be enough to carry Dewpoint into the clinic at the end of 2023, while advancing a suite of 19 other programs. endpts.com/softbank-leads…

Congratulations to the fantastic Dewpoint team on this remarkable achievement! Onward! fiercebiotech.com/biotech/dewpoi…

I am humbled and grateful to be listed as one of Endpoints 20 under 40 in biopharma. A big thanks to the world-class team at Dewpoint, to whom this honor really belongs. Together, anything is possible. Onward! endpts.com/the-201-under-…

Congratulations Isaac Klein on this well-deserved acknowledgement! We are fortunate at Dewpoint to have an oncologist, #condensate scientist, and leader whose knowledge and passion for drug discovery will guide our progress as we advance toward the clinic.

Thanks to DDN for this excellent piece on condensates and drug discovery. drugdiscoverynews.com/biotech-start-…

Nature Reviews Drug Discovery published our groundbreaking perspective, "Modulating biomolecular condensates: a novel approach to drug discovery," a cohesive logic outlining how a deep understanding of condensate biology can revolutionize the drug discovery process. go.nature.com/3dH1TBq

Congrats to the entire Dewpoint team! In this review, we explain the potential of condensate biology to unlock novel therapeutic opportunities for the most difficult diseases. It's a privilege to work with this world-class team on cutting-edge science for the benefit of patients.

“We have the observations that condensates form. Now we need to show why they are important.” My latest on biomolecular phase separation for @NatureNews: nature.com/articles/d4158… Thanks to Jonathon Ditlev TanjaMittag @PappulabWashU Richard Young KnowlesLab Cambridge @Isaac Klein &more

A recent nature paper from The Conrad Lab piqued my attention: FSP1 inhibition via relocalization to condensates, inducing ferroptosis in cancer cells. This is a promising example of a condensate-modifying drug that induces condensate formation. nature.com/articles/s4158…

In the last 5 years, Dewpoint Therapeutics has evolved and applied the science of condensates towards therapeutic discovery. It's a pleasure to share this article highlighting the progress in the field and at Dewpoint. Onward! bit.ly/45YJ9mn